Diginex's explosive growth is an illusion due to a one-time deal, and is not indicative of future growth rates. Read why DGNX stock is a sell.

Galectin Therapeutics Inc. is rated a Hold due to absence of finalized agreement with FDA, combined with a tight runway. Read ...

Pesticides and disinfection by-products are widely detected together in treated drinking water at trace levels worldwide.

P3 Health Partners has seen its price target revised to $12.50 even as fair value per share holds steady at $10.25 and the discount rate remains fixed at 12.5%. This underscores a more nuanced ...

The bank provided more information Thursday as its deal with Fifth Third has drawn litigation alleging a lack of transparency ...

NAV is the definitive metric for evaluating public companies with significant bitcoin reserves. Unlike traditional book value ...

"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." This story is part of a series on navigating the new world of peak protein, from the latest packaged ...

The richest man in the world could more than double his $460.6 billion fortune if SpaceX succeeds in going public next year at a valuation of $1.5 trillion. Elon Musk's stake in his space company ...

Add articles to your saved list and come back to them any time. The richest man in the world could more than double his $US460.6 billion ($689.4 billion) fortune if ...

The richest man in the world could more than double his $460.6 billion fortune if SpaceX succeeds in going public next year at a valuation of $1.5 trillion. Elon Musk’s stake in his space company ...

The richest man in the world could more than double his $US460.6 billion ($689.4 billion) fortune if SpaceX succeeds in going public next year at a valuation of $US1 ...

Every week, X, formerly known as Twitter, and Telegram light up with bold predictions: self-proclaimed prophets promising they’ve found the “next 1000x coin.” The hype is always the same — charts full ...